Advertisement

Drug Eluting Versus Covered Stent for Femoropopliteal Artery Lesions: Results of the ULTIMATE Study

      Objective

      Stent grafts (SG) and drug eluting stents (DES) have emerged to combat intimal hyperplasia. It remains unclear which type of stent yields superior outcomes in femoropopliteal (FP) arterial lesions. This study compared the clinical data between the VIABAHN SG and the Eluvia DES two years after endovascular treatment.

      Methods

      In this retrospective multicentre study, 504 cases with a lesion length > 10 cm treated either with SG or DES were analysed. Ankle brachial index (ABI) measurements were conducted before and after the endovascular procedure, and every three months thereafter. When the ABI dropped ≥ 0.15 compared with the baseline value, a duplex ultrasound was conducted to check stent patency. The outcome measures were stent patency rates, freedom from target lesion revascularisation (TLR), stent thrombosis, and acute limb ischaemia (ALI) accompanying loss of patency rates. Propensity score matching (PSM) was performed to adjust for confounding baseline characteristics.

      Results

      PSM extracted 219 limbs in the SG group and 109 limbs in the DES group. Compared with the SG group, the DES group had statistically significantly higher rates of freedom from TLR (86.0 ± 4.2% vs. 73.1 ± 4.8%, p = .040), and ALI accompanying loss of patency (98.9 ± 1.1% vs. 93.5 ± 1.8%, p = .029) at two years. Primary patency (75.9 ± 5.9% vs. 69.5 ± 5.9%, p = .087) and freedom from stent thrombosis (90.4 ± 3.3% vs. 81.2% ± 3.0%, p = .11) were not statistically significantly different. For lesions ≤ 15 cm, primary patency in the DES group was statistically significantly better than the SG group.

      Conclusion

      FP lesions treated with Eluvia DES had a higher primary patency rate in lesions ≤ 15 cm, freedom from clinically driven TLR and ALI accompanying loss of patency than the VIABAHN SG.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Vascular and Endovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Iida O.
        • Takahara M.
        • Soga Y.
        • Nakano M.
        • Yamauchi Y.
        • Zen K.
        • et al.
        1-year results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): predictors of restenosis.
        JACC Cardiovasc Interv. 2015; 8: 1105-1112
        • Montero-Baker M.
        • Ziomek G.J.
        • Leon L.
        • Gonzales A.
        • Dieter R.S.
        • Gadd C.L.
        • et al.
        Analysis of endovascular therapy for femoropopliteal disease with the Supera stent.
        J Vasc Surg. 2016; 64: 1002-1008
        • Ohki T.
        • Kichikawa K.
        • Yokoi H.
        • Uematsu M.
        • Yamaoka T.
        • Maeda K.
        • et al.
        Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions.
        J Vasc Surg. 2017; 66 (130–42.)
        • Gray W.A.
        • Keirse K.
        • Soga Y.
        • Benko A.
        • Babaev A.
        • Yokoi Y.
        • et al.
        A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
        Lancet. 2018; 392: 1541-1551
        • Müller-Hülsbeck S.
        • Benko A.
        • Soga Y.
        • Fujihara M.
        • Iida O.
        • Babaev A.
        • et al.
        Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent.
        Cardiovasc Intervent Radiol. 2021; 44: 368-375
        • Lammer J.
        • Zeller T.
        • Hausegger K.A.
        • Schaefer P.J.
        • Gschwendtner M.
        • Mueller-Huelsbeck S.
        • et al.
        Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
        J Am Coll Cardiol. 2013; 62: 1320-1327
        • Saxon R.R.
        • Chervu A.
        • Jones P.A.
        • Bajwa T.K.
        • Gable D.R.
        • Soukas P.A.
        • et al.
        Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial.
        J Vasc Interv Radiol. 2013; 24: 165-173
        • Iida O.
        • Takahara M.
        • Soga Y.
        • Yamaoka T.
        • Nanto S.
        • Kuratani T.
        • et al.
        One-year outcomes of heparin-bonded stent-graft therapy for real-world femoropopliteal lesions and the association of patency with the prothrombotic state based on the prospective, observational, multicenter Viabahn stent-graft placement for femoropopliteal diseases requiring endovascular therapy (VANQUISH) study.
        J Endovasc Ther. 2021; 28: 123-131
        • Tsujimura T.
        • Takahara M.
        • Iida O.
        • Soga Y.
        • Katsuki T.
        • Fujihara M.
        • et al.
        Clinical outcomes of polymer-free, paclitaxel-coated stents versus stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
        J Vasc Surg. 2021; 73: 1998-2008
        • Rutherford R.B.
        • Baker J.D.
        • Ernst C.
        • Johnston K.W.
        • Porter J.M.
        • Ahn S.
        • et al.
        Recommended standards for reports dealing with lower extremity ischemia: revised version.
        J Vasc Surg. 1997; 26: 517-538
        • Aboyans V.
        • Ricco J.B.
        • Bartelink M.E.L.
        • Björck M.
        • Brodmann M.
        • Cohnert T.
        • et al.
        ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS).
        Eur Heart J. 2017; 39 (2018): 763-816
        • Björck M.
        • Earnshaw J.J.
        • Acosta S.
        • Bastos Gonçalves F.
        • Cochennec F.
        • Debus E.S.
        • et al.
        Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia.
        Eur J Vasc Endovasc Surg. 2020; 59: 173-218
        • Rocha-Singh K.J.
        • Zeller T.
        • Jaff M.R.
        Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications.
        Catheter Cardiovasc Interv. 2014; 83: E212-E220
        • Ichihashi S.
        • Shibata T.
        • Fujimura N.
        • et al.
        Vessel calcification as a risk factor for in-stent restenosis in complex femoropopliteal lesions after Zilver PTX paclitaxel-coated stent placement.
        J Endovasc Ther. 2019; 26: 613-620
        • Soga Y.
        • Iida O.
        • Hirano K.
        • Suzuki K.
        • Tosaka A.
        • Yokoi H.
        • Nobuyoshi M.
        Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery.
        J Vasc Surg. 2011; 54: 1058-1066
        • McQuade K.
        • Gable D.
        • Pearl G.
        • Theune B.
        • Black S.
        Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
        J Vasc Surg. 2010; 52: 584-590
        • Reijnen M.
        • van Walraven L.A.
        • Fritschy W.M.
        • et al.
        1-year results of a multicenter randomized controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass.
        JACC Cardiovasc Interv. 2017; 10: 2320-2331
        • Bisdas T.
        • Beropoulis E.
        • Argyriou A.
        • Torsello G.
        • Stavroulakis K.
        1-year all-comers analysis of the Eluvia drug-eluting stent for long femoropopliteal lesions after suboptimal angioplasty.
        JACC Cardiovasc Interv. 2018; 11: 957-966
        • Stavroulakis K.
        • Torsello G.
        • Bosiers M.
        • Argyriou A.
        • Tsilimparis N.
        • Bisdas T.
        2-year outcomes of the Eluvia drug-eluting stent for the treatment of complex femoropopliteal lesions.
        JACC Cardiovasc Interv. 2021; 14: 692-701
        • Banerjee S.
        • Sarode K.
        • Mohammad A.
        • Gigliotti O.
        • Baig M.S.
        • Tsai S.
        • et al.
        Femoropopliteal artery stent thrombosis: report from the Excellence in Peripheral Artery Disease registry.
        Circ Cardiovasc Interv. 2016; 9e002730
        • Ichihashi S.
        • Takahara M.
        • Iida O.
        • Suzuki K.
        • Yamaoka T.
        • Maeda K.
        • et al.
        Clinical impact of stent graft thrombosis in femoropopliteal arterial lesions.
        JACC Cardiovasc Interv. 2021; 14: 1137-1147
        • Katsanos K.
        • Al-Lamki S.A.
        • Parthipun A.
        • Spiliopoulos S.
        • Patel S.D.
        • Paraskevopoulos I.
        • et al.
        Peripheral stent thrombosis leading to acute limb ischemia and major amputation: incidence and risk factors in the aortoiliac and femoropopliteal arteries.
        Cardiovasc Interv Radiol. 2017; 40: 351-359